$RMTG News

RMTG's ISSCA Division Announces Successful Santa Cruz, Bolivia Conference, October 23-24

RMTG's ISSCA Division Returns to São Paulo for a Second Brazil Congress, November 20-21

RMTG to Go Ringside at BKFC This Weekend to Capture Content for Its "RMTG Brief" Investor-Awareness Campaign

RMTG's ISSCA Division Expands Global Online Academy With Ten New Curriculum Tracks

RMTG Broadens Longevity Footprint With New ISSCA Certification Across Adjunctive Therapies

RMTG Expands Peptide Education Platform With ISSCA Peptide Certification 2.0 and New Physician Reference Guides

RMTG's ISSCA Division to Host ISSCA 125 Global Summit in Cancún, Mexico

RMTG's ISSCA Division Launches Integrative Fellowship in Point-of-Care Regenerative Medicine through ISSCA AI(TM) Strategy

Regenerative Medical Technology Group, Inc. Details Expanded ISSCA AI(TM) Clinical Intelligence Platform, Including Protocol-Native Engine, Structured Data Assets, and Multi-Line Commercial Model

RMTG's Cellgenic Division Begins Local Commercial Activity in Colombia, Subject to Colombian Regulatory Requirements

RMTG's Cellgenic Commences Commercial Activity in Peru, Extending Its Latin American Footprint

RMTG's Cellgenic Division Introduces MUSE Cell Product Line Across Four International Regions

Regenerative Medical Technology Group's Cellgenic Announces Introduction Of MUSE Cell Product Line In Latin America, Middle East, Europe, And Southeast Asia; Says No Therapeutic Claims Made

RMTG Acquires RMTG.com Domain and Launches New Investor-Focused Website, Advancing Shareholder Engagement

RMTG's Cellgenic Division Launches Natural Killer (NK) Cell Product Line for International Markets

RMTG More Than Quadruples Revenue and Gross Profit in Q2 2026 Versus Q2 2025, With Operating Income Surpassing $560,000

RMTG Provides Details for First-Ever Investor Call to Answer Shareholder Questions

RMTG Expands Cellgenic's Cancún Laboratory Infrastructure with Two Additional ISO 7 Clean Rooms

RMTG to Hold First-Ever Investor Call to Discuss Second Quarter 2026 Results

RMTG Expands Cellgenic Operations Into Argentina, Establishing a Strategic Commercial Hub for Regenerative Medicine in Latin America